New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:59 EDTPRANPrana Biotechnology mentioned cautiously at Summer Street
Summer Street said it believes Prana Biotechnology 's PBT2 is a "long shot" as a treatment for Alzheimer’s and Huntington’s diseases. The firm is skeptical about PBT2's proposed mechanism. Shares of Prana are trading down 57c to $9.35 in pre-market trading.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 5, 2014
16:25 EDTPRANOn The Fly: Closing Wrap
Subscribe for More Information
10:28 EDTPRANHigh option volume stocks
Subscribe for More Information
September 4, 2014
18:50 EDTPRANPrana up 9.8% in after hours trading after receiving FDA orphan designation
Subscribe for More Information
18:06 EDTPRANPrana granted orphan status for treatment of Huntington disease
The FDA posted on its website that Prana Biotechnology has been granted orphan status for its treatment of Huntington's disease. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use